Skip to main content

Table 1 parameters of Weibull function

From: Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States

Parameters name

Average Scale (SD)

Average Shape(SD)

PFS

  

Olaparib

0.0083250(0.0005174)

0.7488611(0.0173989)

Placebo

0.0213860(0.0009352)

0.6347360(0.0129636)

OS

  

Olaparib

0. 005654(0.000355)

0.785309(0.017634)

Placebo

0.0079351(0.0003468)

0.7768977(0.0121948)

  1. SD standardized deviation; PFS progression-free survival; OS overall survival
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us